Recently we described the generation of the prostate tissue-specific monoclonal antibody (MAb) 107-1A4, its expression pattern and preliminary targeting of human prostate cancer xenografts. In this report we demonstrate that the target antigen for MAb 107-1A4 is prostate-specific membrane antigen (P
The identification of prostate-specific antigen
โ Scribed by Richard J. Ablin
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 91 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0887-8013
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Prostate-specific antigen (PSA) has revolutionized the diagnosis and management of men with prostate cancer. Significant advances have been made since the early development of immunoassays. While PSA is useful for staging and monitoring of established disease, it has shown the greatest utility in th
ated with higher pathologic stage and grade in patients undergoing radical prostatectomy (RP). In earlier studies, serum prostate specific membrane antigen (PSMA)
Background. Prostate specific antigen (PSA) is useful as a tumor marker for monitoring patients with prostate cancer after definitive therapy. Limitations have been noted when PSA was used for the early detection of prostate cancer. The use of prostate specific antigen density [PSAD = PSA (ng/ml)/pr
Prostate-specific antigen (PSA) is a wellcharacterized human prostate-specific glycoprotein. PSA has been shown to be the most effective immunohistologic marker for prostate cancer, as well as the most useful serologic test in staging and monitoring prostate cancer and in early detection of recurren
## Background: The objective of this study was to correlate the failure pattern of localized prostate carcinoma after radiotherapy (rt) with pretreatment (pretx) psa and post-rt nadir psa, using systematic biopsies and serum psa in the assessment of outcome. ## Methods: From january 1990 to febru